LifeMD, Inc. (NASDAQ: LFMD), a key player in the virtual primary care sector, reported financial results for the fourth quarter and full year ended December 31, 2025, on March 9, 2026. For the fourth quarter, the company posted a GAAP net loss from continuing operations of $0.04 per share (beating consensus expectations for a larger loss), while revenue reached $46.9 million — a 4% increase year-over-year but slightly below analyst forecasts.
In 2025, LifeMD's revenue grew by 25% to $194.1 million, and adjusted EBITDA increased by 309% to $15.3 million. The fourth quarter saw adjusted EBITDA jump 348% to $4.8 million. These figures highlight the company's strong operational leverage and financial performance over the year.
LifeMD launched oral Wegovy subsequent to year-end, with over 80% of new weight management patients initiating branded therapy. This contributed to record patient sign-ups in the first quarter of 2026. The company ended 2025 with $36.8 million in cash and no debt, positioning it well for future growth investments. LifeMD's benefits infrastructure is on track to cover approximately 220 million Americans by the second quarter of 2026, and its women's health offering is experiencing strong growth.
